Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
The listed adult dose is 300 mg orally daily without routine renal adjustment. During intermittent HD it is given each evening; during continuous HD, 300 mg daily. Select the complete tuberculosis regimen and accompanying monitoring separately.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Preserved historical content; not revalidated as current prescribing guidance.
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Enter at least two characters. Searches stay on this page and are not saved or sent.
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Open / share selected sourcesThese protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Preserved source. Not revalidated as current labeling.
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
The preserved historical tuberculosis treatment descriptions are not presented as an updated TB treatment guideline.
The source lists three initial pulmonary-TB regimens for non-HIV adults/children with susceptible organisms:
1. Daily isoniazid, rifampin and pyrazinamide for 8 weeks, then isoniazid/rifampin daily or 2 to 3 times weekly for 16 weeks. Add ethambutol or streptomycin until isoniazid/rifampin susceptibility is shown; a fourth drug is optional in the source if local isoniazid resistance is <=4%.
2. Daily isoniazid, rifampin, pyrazinamide and streptomycin or ethambutol for 2 weeks, then the same drugs twice weekly for 6 weeks, then isoniazid/rifampin twice weekly for 16 weeks.
3. Isoniazid, rifampin, pyrazinamide and ethambutol or streptomycin three times weekly for 6 months.
All twice/thrice-weekly regimens require directly observed therapy. Know community resistance prevalence; the source suggests avoiding ethambutol in children whose visual acuity cannot be monitored.
HIV/TB: individualize because response may be less satisfactory; malabsorption may warrant antimycobacterial levels, especially advanced HIV, to prevent multidrug resistance.
Extrapulmonary TB: same basic principles, with growing experience for 6 to 9 month regimens despite fewer controlled trials. The source advises 12 months in infant/child miliary, bone/joint and meningeal TB because data are insufficient. Inaccessible sites may require clinical/radiographic assessment rather than bacteriology. Surgery may obtain specimens or treat constrictive pericarditis and spinal compression from Pott disease; adjunctive corticosteroids may reduce pericardial constriction and meningitis neurologic sequelae, especially early.
MDRTB (at least isoniazid/rifampin resistance): individualize by susceptibility with expert consultation. Nonadherence is a major resistance cause; DOT by a provider or responsible observer is recommended for all patients and can be daily, twice or thrice weekly.
Preventive therapy: exclude bacteriologically positive or radiographically progressive disease; evaluate suspected extrapulmonary disease. Adults >30 kg: 300 mg daily. Infants/children: 10 mg/kg daily, maximum 300 mg. If daily adherence cannot be assured, 20 to 30 mg/kg (maximum 900 mg) twice weekly under direct observation. Adequate uninterrupted duration is essential; premature stopping increases relapse and resistance may require regimen changes.
The source mentions the Potts-Cozart urine colorimetric test and urine isoniazid strips for adherence. Concomitant pyridoxine is recommended in malnutrition and neuropathy predisposition, e.g. alcoholism and diabetes.
No adjustment in renal failure.
No adjustment. On dialysis days, give after dialysis.
Open / share this exact local source
The listed adult dose is 300 mg orally daily without routine renal adjustment. During intermittent HD it is given each evening; during continuous HD, 300 mg daily. Select the complete tuberculosis regimen and accompanying monitoring separately.
RDM30-032-isoniazid-1 · Source locator: UCSF - isoniazid; renal/dosing sections and stated qualifiers
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
Read the full coverage report